{
    "clinical_study": {
        "@rank": "102419", 
        "arm_group": [
            {
                "arm_group_label": "Raltegravir", 
                "arm_group_type": "Active Comparator", 
                "description": "coated tablets, oral administration with 240 ml water"
            }, 
            {
                "arm_group_label": "Raltegravir + Faldaprevir", 
                "arm_group_type": "Experimental", 
                "description": "coated tablets and soft gelatine capsule, oral administration with 240 ml water"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of this trial is to investigate effect of faldaprevir on steady state\n      pharmacokinetics of raltegravir.\n\n      The assessment of safety and tolerability will be an additional objective of this trial."
        }, 
        "brief_title": "Investigation of Faldaprevir Effect on Pharmacokinetics of Raltegravir", 
        "completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n        1. healthy male subjects\n\n        Exclusion criteria:\n\n        1. Any relevant deviation from healthy conditions"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 13, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01785160", 
            "org_study_id": "1220.65", 
            "secondary_id": "2012-004872-21"
        }, 
        "intervention": [
            {
                "arm_group_label": "Raltegravir", 
                "description": "low dose oral administration", 
                "intervention_name": "Raltegravir", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Raltegravir + Faldaprevir", 
                "description": "low dose oral administration", 
                "intervention_name": "Raltegravir", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Raltegravir + Faldaprevir", 
                "description": "medium dose oral administration", 
                "intervention_name": "Faldaprevir", 
                "intervention_type": "Drug"
            }
        ], 
        "lastchanged_date": "July 10, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Mannheim", 
                    "country": "Germany"
                }, 
                "name": "1220.65.1 Boehringer Ingelheim Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Investigation of Faldaprevir Effect on Steady State Pharmacokinetics of Raltegravir in Healthy Male and Female Volunteers (an Open-label Trial With Two Periods in a Fixed Sequence)", 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Area under the concentration-time curve of the analyte in plasma at steady state over the uniform dosing interval t", 
                "safety_issue": "No", 
                "time_frame": "up to 132 hours"
            }, 
            {
                "measure": "Maximum measured concentration of the analyte in plasma at steady state over the uniform dosing interval t", 
                "safety_issue": "No", 
                "time_frame": "up to 132 hours"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01785160"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}